Compliance with the FDA Guidances on Investigator Responsibilities and the Form 1572
ISAR-TEST-2 Trial Two-year Clinical and Angiographic Outcomes from a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents versus Polymer-Based Cypher.
Building Quality into Clinical Trials and Avoiding Common Pitfalls Michael E. Marcarelli, PharmD Director, Division of Bioresearch Monitoring Office of.
FDA Final Rule & Revised NCI Guidelines for Expedited Reporting of Adverse Events S. Percy Ivy, MD Associate Chief, Senior Investigator Investigational.
Midterm results - Grades B to A+, mostly low A ethical theories14 rising health care costs7 23andme tests13 how are snps assayed4 GWAS6 critical eval of.
H. Awuoche 1, G.Kiringa 1, V. Nduba 1, E. Mitchell 2 1 KEMRI/CDC Research and Public Health Collaboration 2 KNCV Dutch Tuberculosis Foundation XIX International.
Mc Tiernan - 20th International Nutrition Congress 2013
Eugm 2012 pritchett - application of adaptive sample size re-estimation in event outcome confirmatory trials - 2012 eugm
Adaptive Design Methods in Clinical Trials Shein-Chung Chow, PhD Department of Biostatistics and Bioinformatics Duke University School of Medicine Durham,
October 18, 2011 Device Development in Obesity and Metabolic Disease (DDOMD) Workshop Regulatory Considerations in Device Development Jonathan S. Kahan,
Surrogate Endpoints: The Challenges are Greater than they Seem March 7, 2005 Thomas R. Fleming, Ph.D. Professor and Chair of Biostatistics University of.
A Phase II Study of Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia Xavier Badoux, William Wierda, Susan O'Brien,
